Should patients starting biologics be screened for COVID-19?

Cardenas-de la Garza, Jesus Alberto; Arvizu-Rivera, Rosa I; Galarza-Delgado, Dionicio Angel

Cardenas-de la Garza, Jesus Alberto; Arvizu-Rivera, Rosa I; Galarza-Delgado, Dionicio Angel.

Cardenas-de la Garza JA; Rheumatology, University Hospital "Dr José E González", Universidad Autónoma de Nuevo León, Monterrey, México.
Arvizu-Rivera RI; Internal Medicine, University Hospital "Dr José E González", Universidad Autónoma de Nuevo León, Monterrey, México.
Galarza-Delgado DA; Rheumatology, University Hospital "Dr José E González", Universidad Autónoma de Nuevo León, Monterrey, México dgalarza@medicinauanl.mx.

Ann Rheum Dis ; 81(8): e150, 2022 08.

Article in English | MEDLINE | ID: covidwho-635733

Subject(s)

Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; COVID-19; Antirheumatic Agents/therapeutic use; Arthritis, Rheumatoid/drug therapy; Biological Products/therapeutic use; Humans

Keywords

antirheumatic agents; autoimmune diseases; biological therapy; immune system diseases; tumor necrosis factor inhibitors

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Arthritis, Rheumatoid / Biological Products / Antirheumatic Agents / COVID-19 Limits: Humans Language: English Journal: Ann Rheum Dis Year: 2022 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google